Pluri (PLUR)
Expands cells for therapies, manufacturing and cultivated-food ventures.
Something off on this page? Send us feedback.
Builds cell-expansion systems for contract development and manufacturing, agricultural collaborations, therapeutic candidates and majority-owned food-tech ventures. Revenue has come primarily from CDMO services and AgTech fees, while commercialization spans several early-stage businesses.
Uses a proprietary cell-expansion platform to grow human or plant cells in controlled environments and deploys it across several commercial and development lines. PluriCDMO provides cell-therapy process-development and manufacturing services, while agricultural collaborations generate fees. Cellav is developing regenerative-aesthetics products, and the therapeutic portfolio includes the PLX-PAD and PLX-R18 product candidates.
Extends the platform through Ever After Foods for cultivated meat and fish infrastructure, Kokomodo for cacao ingredients, and Coffeesai for cultivated coffee. Headquarters, research and manufacturing are in Haifa, with commercial and collaboration activity spanning Asia, Europe, the United States and the United Kingdom. Therapeutic candidates require regulatory authorization; food ventures depend on scale-up, economics and food-regulatory processes; core operations remain concentrated in Israel.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.8M · Total debt $34.9M · Total assets $24.9M · Shareholders' equity −$23.0M
- Revenue
- $335.0K
- Operating income
- −$5.5M
- Net income
- −$5.9M
No dividends on record.
| Institutions | 0.25% | 26.5K shares | |
|---|---|---|---|
| 16 holders · as of Jun 30, 2026 | |||
| Insiders | 49.98% | 5.39M shares | |
| 10 holders · as of Aug 24, 2026 | |||
| Other | 49.77% | 5.37M shares | |
| remainder | |||
10.79M company shares as of Sep 16, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (12.34M in the company's Sep 22, 2026 report, 10.79M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Alexandre WeinsteinInsider | 40.34% | 4.35M | filed Jul 1, 2026 |
Yaky YanayInsiderdirector, officer: Chief Executive Officer | 4.61% | 497,758 | filed Dec 8, 2025 |
Alexandre Weinstein Manieu1Insiderdirector, 10 percent owner | 1.77% | 190,769 | filed Aug 24, 2026 |
Zami AbermanInsiderdirector | 1.34% | 144,212 | filed Dec 8, 2025 |
Liat ZaltsInsiderofficer: Chief Financial Officer | 0.86% | 92,767 | filed Dec 8, 2025 |
- Alexandre Weinstein Manieu reports a block also reported by another filer; it is counted once, under that filer.
Insider tradesForm 4
No open-market trades in the last 12 months.
- Steakholder Foods (ADR)
Alternative-protein production technology for cultivated-meat partnerships.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Pluri | $1.04 | −2.80% | $11.5M | — | — | 11.4 | −15.8% |
| Steakholder Foods (ADR) | $1.91 | −1.03% | $1.3M | — | — | — | — |